Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: A feasibility study

Cancer

Volumn 101, Issue 1, 2004, Pages 178-182

  Culine, Stéphane ^a   Romieu, Gilles ^a   Fabbro, Michel ^a   Becht, Catherine ^c   Cupissol, Didier ^a   Guillemare, Catherine ^a   Bleuse, Jean Pierre ^b   Lotz, Véronique ^b   Gourgou, Sophie ^a  

^a CENTRE VAL D AURELLE   (France)

^b SANOFI   (France)

^c Parc Euromédecine ^*

Author keywords

Docetaxel; Dose intensity; Feasibility; Hematopoietic growth factor; Lenograstim

Indexed keywords

DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLADDER CARCINOMA; BREAST CARCINOMA; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 3042577833     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20351     Document Type: Article

References (9)

1. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere®): a semi-synthetic analogue of (Taxol®). J Natl Cancer Inst. 1991;83:288-291.
2. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of (Taxotere®) (RP 56076) administered as a 24-hour infusion. Cancer Res. 1993;53:523-527.
3. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of (Taxotere®) administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993;11:950-958.
4. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of (Taxotere®) (RP 56076; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993;53:1037-1042.
5. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458-1467.
6. Miller AB, Hoogstraten B, Staquet B, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
7. Seibel NL, Blaney SM, O'Brien M, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Chidren's Cancer Group trial. Clin Cancer Res. 1999;5:733-737.
8. Gonçalves A, Viret F, Ciccolini J, et al. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res. 2003;9;102-108.
9. Paciucci PA, Raptis G, Bleiwess I, Weltz C, Lehrer D, Gurry R. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer. Anticancer Drugs. 2002;13:791-795.